Results 151 to 160 of about 1,091,220 (265)

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Linking Inflammation to Reduced Food Intake in Advanced Cancer: A Prospective Observational Study. [PDF]

Curr Oncol
Bye A, Balstad TR, Ervik Raaness I, Solheim TS, Habberstad R, Klepstad P, Løhre ET, Dajani OF, Kaasa S, Aass N, Vagnildhaug OM.   +10 more
europepmc   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Palliative Care Coaching for Family Caregivers of Patients With Advanced Cancer: A Randomized Clinical Trial.

JAMA Netw Open
Odom JN, Azuero A, Taylor RA, Young Pierce J, McGowen CL, Pisu M, Rocque G, Reed RD, Wells R, Gazaway S, Mollman S, Williams GR, Huang CS, Engler S, Bakitas MA.   +14 more
europepmc   +1 more source

Development of novel plasma proteomic biomarkers for cancer-associated thrombosis in an advanced cancer cohort. [PDF]

J Thromb Haemost
Preeti, Ranjan M, Pham D, Bueno JL, Resende MM, Scheurer ME, Amos CI, Cheng C, Li A.   +8 more
europepmc   +1 more source

ZW4864‐mediated inhibition of the β‐catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer

Molecular Oncology, EarlyView.
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi, Mandy Berndt‐Paetz, Eileen Lerner, Gregoire Najjar, Anca Azoitei, Krishna Pal Singh, Shailendra Kumar Gupta, Olaf Wolkenhauer, Cagatay Günes, Otmar Huber, Marc‐Oliver Grimm, Daniel Steinbach   +11 more
wiley   +1 more source

Impact of Spiritual Wellbeing in Advanced Cancer Patients Receiving Genomic Test Results. [PDF]

Psychooncology
Best MC, Descallar J, Simpson G, Napier CE, Bartley N, Ballinger ML, Goldstein D, Thomas DM, Tucker KM, Butow P.   +9 more
europepmc   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Validation of the Double Awareness Scale: A Novel Measure of Psychological Adaptation to Advanced Cancer. [PDF]

Psychooncology
Miljanovski M, Mah K, Li A, Rydall A, McConnell MH, Shapiro GK, Hannon B, Zimmermann C, Rodin G.   +8 more
europepmc   +1 more source

Advances in cancer nanomedicine.

Cancer biology & medicine, 2015
Lin-Tao Cai, Zong-Hai Sheng
openaire   +3 more sources